pipette
ESEspañol

Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer

Apostolia Maria Tsimberidou, Christopher R. Cabanski, Alexandra Drakaki, Danny N. Khalil, Bilal Ahmed Siddiqui, Sreyashi Basu, Kwame Okrah, Diane M. Da Silva, Shikha Gautam, Farah A. Alayli, Mike Schachter, Justin P. Fairchild, Wai Chin Foo, Silvia Boffo, Jamie Arnott, Ute Dugan, Sumit Kumar Subudhi, Padmanee Sharma

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
Although higher ipilimumab doses were tolerable, I1+N360 achieved similar disease control and immune activation with a more favorable safety profile.

Appeared: Friday, October 16. Science Advances. Peer-reviewed journal.

DOI: 10.1126/sciadv.aee8730